Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377591 | 1.00 | TAAR1 (0.42) | TAAR1KDM4EADRA2AADRA2CCYP2D6 | |
| SCHEMBL450918 | 1.00 | TAAR1 (0.42) | TAAR1KDM4EADRA2AADRA2CCYP2D6 | |
| SCHEMBL16202960 | 0.76 | TAAR1 (0.41) | TAAR1KDM4EADRA2AADRA2CCYP2D6 | |
| SCHEMBL16202956 | 0.76 | TAAR1 (0.41) | TAAR1KDM4EADRA2AADRA2CCYP2D6 | |
| SCHEMBL11859945 | 0.76 | TAAR1 (0.41) | TAAR1KDM4EADRA2AADRA2CCYP2D6 | |
| SCHEMBL12053468 | 0.74 | MEN1 (0.40) | KDM4EHIF1AALDH1A1 | |
| SCHEMBL2561541 | 0.74 | CYP3A4 (0.44) | CYP2D6LMNAALDH1A1TSHR | |
| SCHEMBL2560254 | 0.74 | IDO1 (0.39) | LMNAALDH1A1 | |
| SCHEMBL2554184 | 0.74 | CYP2A6 (0.40) | ALDH1A1 | |
| SCHEMBL3901288 | 0.74 | ADRB2 (0.52) | LMNAHIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20130338181-A1 | TREATMENT OF EFFECT OF CHEMICALS WITH THEIR ULTRADILUTE STEREOISOMERS | KUZEFF REINHARD MICHAEL (AU) | 2013-12-19 | — | — | US | disclosed |
| EP-2539320-A1 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg (NL) | 2013-01-02 | — | — | EP | disclosed |
| US-20120329704-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIEENTENZORG (NL) | 2012-12-27 | — | — | US | disclosed |
| US-20120136020-A1 | TREATMENT OF EFFECT OF CHEMICALS WITH THEIR ULTRADILUTE STEREOISOMERS | SEMPACH PTY LTD (AU) | 2012-05-31 | — | — | US | disclosed |
| WO-2011103932-A1 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS | VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIËNTENZORG (NL) | 2011-09-01 | — | — | WO | disclosed |
| EP-1487448-A4 | TREATMENT OF EFFECT OF CHEMICALS WITH THEIR ULTRADILUTE STEREOISOMERS | SEMPACH PTY LTD (AU) | 2007-04-25 | — | — | EP | disclosed |
| US-20050119350-A1 | Treatment of effect of chemicals with their ultradilute stereoisomers | SEMPACH PTY LTD ACN 078 746 522 (AU) | 2005-06-02 | — | — | US | disclosed |
| EP-1487448-A1 | TREATMENT OF EFFECT OF CHEMICALS WITH THEIR ULTRADILUTE STEREOISOMERS | Sempach PTY Ltd (AU) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003072105-A1 | TREATMENT OF EFFECT OF CHEMICALS WITH THEIR ULTRADILUTE STEREOISOMERS | SEMPACH PTY LTD (AU) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329704-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS | NGLY1, NPR3, NPR1 | TAAR1 1681/4885KDM4E 2797/4885ADRA2A 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.